Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00116103 · ClinicalTrials.gov registry record · Phase 2

A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma

A Phase 2 study of Asthma, sponsored by Astellas Pharma.

Completed
Registry status
Phase 2
Development phase
20
Study locations

NCT00116103: Completed Phase 2 study of Asthma, sponsored by Astellas Pharma.

NCT00116103 is a Phase 2 study of Asthma that has completed, run by Astellas Pharma. The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00116103, a Phase 2 study of Asthma, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 2
Development phase
20
Study locations

Study Summary

The purpose of this study is to determine the safety and effectiveness of tacrolimus inhalation aerosol in subjects with persistent asthma.

Conditions Studied

Interventions

  • DRUG Tacrolimus Inhalation Aerosol

Study Locations (20)

California

  • - Encinitas
  • - Los Angeles
  • - San Diego
  • - San Jose

Florida

  • - Daytona Beach
  • - Miami

Arizona

  • - Scottsdale

Colorado

  • - Denver

Idaho

  • - Boise

Illinois

  • - River Forest

Indiana

  • - South Bend

Missouri

  • - St Louis

Trial Details

FieldValue
Start Date 2005-06
Est. Completion 2006-04
Phase Phase 2
Astellas Pharma

165 total trials

What the finished NCT00116103 record still lists

NCT00116103 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Tacrolimus Inhalation Aerosol is the first listed.

NCT00116103 names 20 study sites across 16 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00116103 about?

NCT00116103 is a clinical study titled "A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma". The purpose of this study is to determine the safety and effectiveness of tacrolimus inhalation aerosol in subjects with persistent asthma.

What is the current status of trial NCT00116103?

This trial is currently completed. It is a Phase 2 study. The study started on 2005-06. Estimated completion is 2006-04.

What conditions does trial NCT00116103 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT00116103?

The interventions under investigation include: Tacrolimus Inhalation Aerosol (DRUG).

Who is sponsoring clinical trial NCT00116103?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00116103 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00116103, the US trial registry maintained by the National Library of Medicine. NCT00116103 (unsized enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.